Introduction {#Sec1}
============

The ongoing novel coronavirus (COVID-19) pandemic, involving a virus originally identified in Wuhan, China, has forced several countries to take unprecedented public health measures. As health professionals and policymakers try to shield those at highest risk, better defining the risk factors for severe COVID-19 has been identified as an urgent research priority (Cowling and Leung [@CR3]; Lipsitch et al. [@CR14]).

COVID-19 has a seemingly variable clinical presentation and progression. According to data from China, an estimated 10--15% of mild cases progress to severe, and 15--20% of severe cases go on to become critical, with many of those in the latter category requiring treatment in intensive care units (ICU) (Wu and McGoogan [@CR23]). To maximise the use of scarce health system resources, it is imperative to identify those at risk of progressing to severe and critical illness with COVID-19. It is thought that age and underlying chronic conditions (or comorbidities) increase the risk of severe COVID-19 (Centers for Disease Control and Prevention [@CR1]), but the differential effect of various comorbidities remains unclear, and current guidance is largely based on expert consensus rather than observational data.

In order to build on existing knowledge, a better understanding of the symptoms and comorbidities (which are the first and most routinely collected components of patient data) related to COVID-19 severity is required. There have been a number of meta-analyses on COVID-19 severity conducted to date (Henry and Lippi [@CR7]; Yang et al. [@CR25]; Li et al. [@CR11]), but none of these investigated the predictive value of symptoms, nor separated severe disease from ICU admission (which represents the upper end of severity) when investigating the impact of comorbidities. Through separately analysing patients admitted to ICU, this study aims to better assess the most important symptoms and comorbidities for those with very severe (or critical) disease. This will help to inform public health actions aiming to protect the most vulnerable from acquiring COVID-19 and may also guide efforts on early intervention and resource allocation, through informing the design of clinical pathways and risk stratification tools. Deaths from COVID-19 can also be investigated as an outcome of very severe (or critical) disease. But, if done through routine sources (for instance, using death certificates), this would not allow an analysis of predictive symptoms. Moreover, since many patients admitted to ICU with COVID-19 survive, predictors for death may differ from those for ICU admission.

The primary aim of this study was to conduct a systematic review and meta-analysis, aggregating all available data from published studies, of symptoms and comorbidities predictive for severe disease and ICU admission with COVID-19.

Methods {#Sec2}
=======

Retrieval of studies {#Sec3}
--------------------

This study was prospectively registered on PROSPERO (CRD42020172126). Identification of relevant existing literature was performed by an online search in three databases: MEDLINE, EMBASE and Global Health, for studies published from 1st January 2019 to 5th March 2020. The MESH headings (keywords) searched were 'nCoV\*' or 'coronavirus' or 'SARS-2-CoV' or 'COVID\*' and 'symptom\*' or 'clinical' or 'predict\*' or 'characteristic\*' or 'co-morbidit\*' or 'comorbidit\*' or 'condition\*'. Two reviewers (VG, JMY) independently screened the list of titles and abstracts, and the full text of chosen manuscripts. Disagreements on which manuscripts to include during both title and abstract screen, and the subsequent full-text analysis, were discussed until a conclusion was reached. In addition to the MEDLINE/EMBASE/Global Health search, citation tracking was used to identify any remaining relevant published studies, though none were identified. Unpublished and preprint studies were not retrieved due to uncertain data quality.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

All studies evaluating individual symptoms and comorbidities in predicting severe infection (as measured by disease severity criteria, or ICU admission) were included. All studies of any design, from any time since the outbreak started (in December 2019), were eligible, except case reports of individual patients or literature reviews. To avoid selection bias, no subjective quality criteria were applied to the studies for inclusion. Exclusion criteria included: (1) studies of exclusively paediatric or pregnant patients, due to the varying presentation of COVID-19 in these groups, (2) insufficient data on symptoms/comorbidities on admission in either severe or non-severe disease groups (or ICU and non-ICU groups), (3) coronavirus strains other than COVID-19 and (4) studies not written in English, because of practical limitations with translation.

Data extraction {#Sec5}
---------------

Two reviewers independently extracted data from the included studies for both narrative synthesis and statistical analysis. From each study, various details including the study population, investigated predictive symptoms or comorbidities, and the definitions used to measure outcomes, were extracted into Microsoft Excel. These details are presented by study in Table [1](#Tab1){ref-type="table"}. The number of patients in each study, both with and without each symptom or comorbidity, was extracted for statistical analysis (described below).Table 1Studies investigating the predictive value of symptoms/comorbidities for severe COVID-19 or intensive care unit admission. China (2020)StudyYear and locationDesignPopulation (*n*)Median age (IQR)Severe COVID-19 cases (*N*)Number of symptoms (comorbidities) investigatedDuration of symptoms before admission (median number of days, IQR)Definition of outcome measureKey reported findings relating to severe COVID-19/intensive care unit (ICU) admissionQuality of study^a^Guan et al. ([@CR5])11 December 2019--29 January 2020, 522 hospitals from 30 provinces in ChinaRetrospective multi-centre cohort*n* = 1099, 58.1% male47 (35--58)*N* = 67 primary end point*N* = 173 severe14 (9)N/AComposite end point: ICU admission, use of mechanical ventilation or death.Severity defined as per American Thoracic Society guidelines for community-acquired pneumoniaPatients with severe disease were older than those with non-severe disease by a median of 7 years. Comorbidities were also more common among patients with severe disease (38.7% vs. 21.0%) including COPD (3.5% vs. 0.6%), diabetes (16.2% vs. 5.7%), hypertension (23.7% vs. 13.4%) and coronary heart disease (5.8% vs. 1.8%)+Huang et al. ([@CR8])16 December 2019--2 January 2020, Wuhan, ChinaRetrospective multi-centre cohort*n* = 41, 73% male49 (41--58)*N* = 138 (6)ICU care = 7 (4--8)No ICU care = 7 (4--8.5)ICU admission (requiring high-flow nasal cannula or higher-level oxygen support measures to correct hypoxaemia)Dyspnoea was significantly more common in the ICU care group (92% vs. 37%,*p* = 0.001). The presence of various comorbidities was similar across both groups++Li et al. ([@CR12])January--February 2020, 3 hospitals, ChinaRetrospective multi-centre cohort*N* = 83, 53% maleMean age = 45.5 (SD 12.3)*N* = 258 (4)Severe/critical = 8 (6--12)Non-severe/critical = 6 (3--8.5)Severe/critical patients = any of respiratory distress with RR ≥ 30 breaths per minute, oxygen saturation ≤ 93%, PaO2/FiO2 ≤ 300 mmHg, required mechanical ventilation, shock occurred or other organ failure needing ICU careOn univariable logistic regression, factors significantly more predictive for severe/critical cases were age \> 50 (OR 7.60, 95% CI 2.6--21.7), comorbidities (OR 10.6, 95% CI 2.93--38.4), dyspnoea (OR 10.9, 95% CI 2.07--57.2), chest pain (OR 10.9, 95% CI 1.15--102.8), cough (OR 9.95, 95% CI 1.25--79.6) and expectoration (OR 4.88, 95% CI 1.51--15.8)+Tian et al. ([@CR19])20 January--10 February 2020, Beijing, ChinaRetrospective multi-centre cohort*n* = 262, 48.5% male47.5 (range = 1--94)*N* = 465 (0)Severe = 5.2 (range 0.6--9.8)Non-severe = 4.4 (range 0.9--7.9)Mild case = confirmed case with fever, respiratory symptoms and radiographic evidence of pneumonia.Severe case = mild case with dyspnoea or respiratory failureDyspnoea was the only symptom found to be significantly more common in severe cases compared to non-severe cases (32.6% vs. 1.4%, p \< 0.001)+Wang et al. ([@CR21])1--28 January 2020, Zhongnan Hospital, Wuhan, ChinaRetrospective single-centre cohort*n* = 138, 54.3% male65 (IQR 42--68)*N* = 3614 (9)ICU = 8 (4.5--10)Non-ICU = 6 (3--7)ICU admission (development of organ dysfunction)ICU patients (*n* = 36), compared with patients not treated in the ICU (*n* = 102), were older (median age, 66 years vs. 51 years), were more likely to have underlying comorbidities (26 \[72.2%\] vs. 38 \[37.3%\]), and were more likely to have dyspnoea (23 \[63.9%\] vs. 20 \[19.6%\]) and anorexia (24 \[66.7%\] vs. 31 \[30.4%\])++Xu et al. ([@CR24])January--February 2020, ChinaRetrospective single-centre cohort*n* = 50, 58% male10% \< 18 years, 60% 18--50 years, 30% \> 50 years*N* = 138 (0)N/ASevere case = respiratory distress with RR \> 30, SpO2 \< 93% or PaO2/FiO2 \< 300 mmHg.Critical case = respiratory failure needing mechanical ventilation, shock or combination with other organ failure needing ICU careThe most common symptoms were mild fever (37.3C--38C) in 44% of all cases (51% vs. 23% in severe/critical vs. mild/moderate groups), and cough in 40% of all cases (46% vs. 38% for severe/critical vs. mild/moderate)--Zhang et al. ([@CR27])16 January--3 February 2020, No. 7 Hospital of Wuhan, ChinaRetrospective single-centre cohort*n* = 140, 50.7% male57 (range 25--87)*N* = 5810 (22)Severe = 7 (6--12)Non-severe = 8 (5--11)Severe = respiratory distress with RR ≥ 30, SpO2 ≤ 93% or PaO2/FiO2 ≤ 300Having any comorbidity was more common in severe disease patients compared to non-severe (79.3% vs. 53.7%,*p* = 0.002). Cough (84.9% vs. 67.2%,*p* = 0.02) was significantly more common in the severe group, and nausea significantly less common, compared with the non-severe group (8.8% vs. 23.2%,*p* = 0.02)+^a^Quality of included studies (% of STROBE checklist criteria met, \< 55% = −, 55--65% = + , \> 65% = ++)

Predictors and outcomes {#Sec6}
-----------------------

The symptoms or comorbidities presented were investigated in at least three included studies. Where studies measured symptoms ambiguously (including abdominal pain/diarrhoea (Li et al. [@CR12]), myalgia/fatigue (Huang et al. [@CR8]) and nausea/vomiting (Guan et al. [@CR5])), these data were excluded. Some studies reported heart disease and stroke separately (Guan et al. [@CR5]; Wang et al. [@CR21]; Zhang et al. [@CR27]). To allow comparability between studies for meta-analysis, these were grouped into a single predictor (cardiovascular disease). One study was excluded from the analysis of dyspnoea as a predictor of severity, as dyspnoea was part of the definition for severity used by the authors (Tian et al. [@CR19]). Smoking was not included in meta-analyses as the three papers including data on smoking (Guan et al. [@CR5]; Huang et al. [@CR8]; Zhang et al. [@CR27]) were distributed across both severe and ICU groups, rather than reporting consistently on one (or both) of these outcome measures.

For disease severity, the included studies varied in their differentiation of patients' disease status, with classifications of 'mild, moderate, severe and critical' (Xu et al. [@CR24]), 'ordinary and severe/critical' (Li et al. [@CR12]), 'common and severe' (Tian et al. [@CR19]) and 'non-severe and severe', disease (Guan et al. [@CR5]; Zhang et al. [@CR27]). The first outcome measure used was severe (including both severe and critical cases) versus non-severe disease. For ICU admission, the included studies varied in their definition of ICU admission, with classifications of 'ICU, mechanical ventilation or death and non-ICU' (Guan et al. [@CR5]), and 'ICU and non-ICU' (Huang et al. [@CR8]; Wang et al. [@CR21]). The second outcome measure used was ICU admission (including ICU, mechanical ventilation or death, where data were grouped together) versus non-ICU admission.

Statistical analysis {#Sec7}
--------------------

Patient numbers were aggregated across all included studies for each group included in the meta-analysis. Gender was compared between groups using the Chi-square test in STATA (StataCorp. [@CR17]). This was not possible for age due to a lack of individual-level data. The predictive value of symptoms and comorbidities for each of severe disease and ICU admission was estimated with random effects meta-analysis in STATA. Random effects models were used to account for between study heterogeneity (Hedges and Vevea [@CR6]), which was estimated with Tau-squared. This provided a pooled odds ratio (pOR), 95% confidence intervals and a *p* value, for each symptom or comorbidity. A *p* value of \< 0.05 was used as a marker for evidence of significant association.

Preprint {#Sec8}
--------

An early version of this manuscript was uploaded to the 'medRxiv' preprint server in order to contribute to the rapidly evolving scientific knowledge on COVID-19 (Jain and Yuan [@CR10]).

Results {#Sec9}
=======

The PRISMA flow diagram (Fig. [1](#Fig1){ref-type="fig"}) illustrates the process for selection of papers in this study.Fig. 1PRISMA flow diagram of included studies. China (2020)

Literature search {#Sec10}
-----------------

The initial search on MEDLINE, EMBASE and Global Health produced 2259 results. After removing duplicates and applying exclusion criteria, there were 42 papers meeting our criteria from title and abstract analysis. On further review, the majority of these studies did not compare proportions of patients with symptoms or comorbidities between severe (or ICU admitted) and non-severe disease (or non-ICU admitted) groups. The reasons for all study exclusions are outlined in Fig. [1](#Fig1){ref-type="fig"}. A total of seven studies were selected for inclusion.

Description of included studies {#Sec11}
-------------------------------

Table [1](#Tab1){ref-type="table"} shows details of all included studies including reported findings pertaining to symptoms and comorbidities related to severe disease or ICU admission. These seven studies reported on a total of 1813 patients. All included studies were retrospective cohort studies in design, conducted between December 2019 and February 2020 in China, during the novel coronavirus (SARS-CoV-2) outbreak. Guan et al. ([@CR5]) conducted the largest study with 1099 COVID-19 patients, whilst Huang et al. ([@CR8]) included 40 patients in their study. The number of symptoms investigated varied from five in one study (Tian et al. [@CR19]) to 14 in others (Guan et al. [@CR5]; Wang et al. [@CR21]). The range of comorbidities investigated varied greatly with two studies not including any (Tian et al. [@CR19]; Xu et al. [@CR24]) and one including 22 comorbidities (Zhang et al. [@CR27]).

Table [2](#Tab2){ref-type="table"} displays the median age and gender of severe and non-severe disease, and ICU and non-ICU admitted, patients, after aggregating all studies. The median age was 62.4 years for ICU-admitted patients compared to 46 years for non-ICU patients, and 49.4 years for severe compared to 41.7 years for non-severe disease patients.Table 2Total population from included studies. China (2020)ICU admission (*N* = 116)Non-ICU admission (*N* = 1162)*p* valueSevere disease (*N* = 315)Non-severe disease (*N* = 1319)*p* valueMedian age (years)^a^62.446.0--49.441.7--Male (%)67.257.10.0457.555.10.46*ICU* intensive care unit^a^Median unavailable for Li et al. ([@CR12]) and Xu et al. ([@CR24])

Quality of included studies {#Sec12}
---------------------------

All included studies were retrospective cohort studies and were critically appraised using the STROBE checklist (von Elm et al. [@CR20]). The 22 items on the STROBE checklist were formulated into 47 individual indicators, against which each study was marked. The proportion of included studies which met each individual appraisal indicator is illustrated in the online resource (Figure S1). Each paper was assigned an overall quality score based on the percentage of STROBE checklist criteria met (\< 55% = −, 55--65% = +, \> 65% = ++), as outlined in Table [1](#Tab1){ref-type="table"}.

Appraising with the STROBE checklist highlighted several major weaknesses in the included studies. Firstly, there was no consistent definition on what constituted severe disease. The WHO-China Joint Mission on COVID-19 defined a severe case as tachypnoea (≥ 30 breaths/min) or oxygen saturation ≤ 93% at rest, or PaO2/FiO2 \< 300 mmHg (WHO-China Joint Mission [@CR22]). Critical cases were defined as respiratory failure requiring mechanical ventilation, shock or other organ failure that requires intensive care. Although the above criteria were used in some included studies (Xu et al. [@CR24]; Li et al. [@CR11]), many defined only one out of severe and critical, with one (Li et al. [@CR12]) using a definition for a single severe/critical cohort. One study reported both severe and critical cases (Guan et al. [@CR5]), using criteria set by the American Thoracic Society. Secondly, the time at which severity of disease was determined was not always clear. Severity was assessed on admission in two studies (Guan et al. [@CR5]; Zhang et al. [@CR27]), whilst three studies did not specify when severity was assessed (Li et al. [@CR12]; Tian et al. [@CR19]; Xu et al. [@CR24]). It is possible, therefore, that the non-severe group included patients who went on to later develop severe disease. Thirdly, the time point at which symptoms were measured varied from illness onset (via recall) (Huang et al. [@CR8]; Wang et al. [@CR21]; Zhang et al. [@CR27]; Tian et al. [@CR19]) to clinical presentation (Guan et al. [@CR5]; Xu et al. [@CR24]). In one study, it was not clear when symptoms were measured (Li et al. [@CR12]). Finally, no study specified how each individual symptom or comorbidity was measured. For instance, it was unclear whether fever was objectively measured, and if so, how or by whom.

Meta-analysis {#Sec13}
-------------

Table [3](#Tab3){ref-type="table"} shows the odds ratios, 95% confidence intervals and *p* values for the individual symptoms and comorbidities that were investigated in at least three of the included studies, for both severe COVID-19 and ICU admission, respectively. Forest plots of the predictive symptoms and comorbidities for both severe COVID-19 and ICU admission are illustrated in Fig. [2](#Fig2){ref-type="fig"}. A total of seven symptoms were included in the model for severe disease and six for ICU admission, as well as four comorbidities in both. The most prevalent symptoms in the severe group were cough (70.5%), fever (64.1%) and fatigue (44.5%); in the ICU group these were cough (67.2%), fever (62.9%) and dyspnoea (61.2%). The most prevalent comorbidities in the severe group were hypertension (25.4%) and diabetes (16.8%) and in the ICU group were hypertension (40.5%) and cardiovascular disease (CVD) (24.1%).Table 3Estimated pOR from meta-analysis for symptoms/comorbidities and both severe COVID-19 and intensive care admission. China (2020)PredictorSevere COVID-19Pooled odds ratio (95% CI)*p* valueTau-squaredNumber of studies (*n* = 5)Number of severe disease patientsNumber of non-severe disease patientsPrevalence in severe group (%)Prevalence in non-severe group (%)Male1.15 (0.89--1.48)0.29\< 0.001518172757.555.1Dyspnoea3.70 (1.83--7.46)\< 0.0010.24410016237.214.7Cough1.63 (1.03--2.60)0.040.11522281870.562.0Fever1.17 (0.88--1.56)0.28\< 0.001520271164.153.9Fatigue1.44 (0.76--2.72)0.260.25412945744.536.2Myalgia1.32 (0.89--1.96)0.16\< 0.00133914818.514.5Expectoration1.75 (0.63--4.83)0.280.5237232034.131.3Headache1.16 (0.78--1.74)0.47\< 0.00143414713.211.9COPD6.42 (2.44--16.9)\< 0.001\< 0.00131274.70.7CVD2.70 (1.52--4.80)0.001\< 0.001321328.23.0Hypertension1.97 (1.40--2.77)\< 0.001\< 0.00136514725.413.8Diabetes3.12 (1.00--9.75)0.050.613436216.85.8PredictorIntensive care unit admissionPooled odds ratio (95% CI)*p* valueTau-squaredNumber of studies (*n* = 3)Number of ICU-admitted patientsNumber of non-ICU-admitted patientsPrevalence in ICU group (%)Prevalence in non-ICU group (%)Male1.55 (1.02--2.36)0.04\< 0.00137866467.257.1Dyspnoea6.55 (4.28-- 10.0)\< 0.001\< 0.00137119961.210.2Cough1.06 (0.69--1.62)0.79\< 0.00137878067.267.1Fever0.75 (0.45--1.24)0.27\< 0.00137357862.949.7Expectoration0.87 (0.56--1.36)0.55\< 0.00133338528.433.1Headache0.90 (0.46--1.73)0.74\< 0.0013111519.513.0Diarrhoea1.83 (0.86--3.90)0.11\< 0.001310478.64.0COPD17.8 (6.56--48.2)\< 0.001\< 0.00131169.50.5CVD4.44 (2.64--7.47)\< 0.001\< 0.0013284724.114.4Hypertension3.65 (2.22--5.99)\< 0.0010.0334716740.514.4Diabetes2.72 (0.70--10.6)0.151.013277623.26.5*ICU* intensive care unitFig. 2Forest plots of the symptoms/comorbidities predictive for severe COVID-19 (**a**, **c**, **e**, **g**) and intensive care unit admission (**b**, **d**, **f**, **h**). China (2020)

Men were 1.55 times more likely than women to be admitted to ICU (95% CI 1.02--2.36) but not at a significantly increased risk of being in the severe group. Dyspnoea was the only symptom significantly associated with both severe disease (pOR 3.70, 95% CI 1.83--7.46) and ICU admission (pOR 6.55, 95% CI 4.28--10.0), being more strongly associated with the latter. Cough was associated with severe disease (pOR 1.63, 95% CI 1.03--2.60), but not ICU admission. The remaining symptoms analysed were not associated with either outcome. Chronic obstructive pulmonary disease (COPD), CVD and hypertension were the comorbidities significantly predictive for both severe disease and ICU admission. The pORs for severe disease were as follows: COPD (6.42, 95% CI 2.44--16.9), CVD (2.70, 95% CI 1.52--4.80) and hypertension (1.97, 95% CI 1.40--2.77). COPD, CVD and hypertension were more strongly associated with ICU admission, compared with severe disease, with pORs of 17.8 (95% CI 6.56--48.2), 4.44 (95% CI 2.64--7.47), and 3.65 (95% CI 2.22--5.99), respectively. In contrast, diabetes was of borderline significance in predicting severe disease (pOR 3.12, 95% CI 1.0--9.75), but not ICU admission (pOR 2.72, 95% CI 0.70--10.6), although the Tau-squared value for the latter was unusually high implying a high level of heterogeneity.

Discussion {#Sec14}
==========

Key findings {#Sec15}
------------

COVID-19 severity was not consistently defined across included studies. All studies were of adequate quality, considering the context, and two were of relatively high quality. The ICU group were older compared to the non-ICU group, with a significantly higher proportion of males.

The most prevalent symptoms in the severe disease group were cough, fever and fatigue and in the ICU admitted group were cough, fever and dyspnoea. The most prevalent conditions in the severe group were hypertension and diabetes and in the ICU group were hypertension and CVD. Males were not at an increased risk of severe disease, but 1.55 times more likely to have an ICU admission compared to females. Dyspnoea was the only symptom significantly associated with disease severity and ICU admission, alongside various comorbidities (COPD, CVD and hypertension). All of these factors were more strongly associated with ICU admission than disease severity. Patients with dyspnoea were 6.6 times more likely to have an ICU admission compared to those without dyspnoea. Although COPD was relatively uncommon, even in ICU patients, it was by far the most strongly predictive comorbidity for ICU admission. Those with CVD and hypertension were 4.4 and 3.7 times more likely to have an ICU admission, respectively, compared to patients without the comorbidity.

Building on existing knowledge {#Sec16}
------------------------------

Consistent with Sun et al.'s ([@CR18]) meta-analysis of symptoms in 50,466 COVID-19 patients (Sun et al. [@CR18]) and the WHO-China joint mission on COVID-19 (WHO-China Joint Mission [@CR22]), cough and fever were the most common symptoms found in our analysis. We found that the prevalence of dyspnoea in the ICU group was 67.2%, compared with 10.2% in the non-ICU group. Although dyspnoea by definition may be indicative of lung involvement and therefore more severe disease, there have been reports of 'silent hypoxia', where oxygen saturations can fall and precipitate acute respiratory failure in the absence of dyspnoea and other symptoms of respiratory distress (Gattinoni et al. [@CR4]). The significant association of dyspnoea in this analysis with severe disease and ICU admission suggests that most patients who progress to severe illness do not have 'silent hypoxia'. It should be noted though, that the reported strength of dyspnoea as a predictor for severe disease and ICU admission could be affected by selection bias since patients without dyspnoea (but with severe disease) may be less likely to be admitted to hospital in the first instance. The median time from illness onset to dyspnoea is 5--8 days, and the median time from illness onset to ICU admission has been reported as 10--12 days (Centers for Disease Control and Prevention [@CR2]). One of the studies included in our meta-analysis found patients admitted to ICU had a longer duration of symptoms before hospitalisation compared to those not requiring ICU care (Wang et al. [@CR21]). Given the importance of dyspnoea in predicting ICU admission, future research should aim to assess the value of early hospital admission, clinical intervention and close community-based monitoring in patients with dyspnoea.

The findings reported here are in keeping with current knowledge that the elderly and those with comorbidities are more susceptible to severe infection (Centers for Disease Control and Prevention [@CR2]; WHO-China Joint Mission [@CR22]). A previous systematic review of 19 prevalence studies, including 2874 patients, found hypertension (18.6%) and cardiovascular disease (14.4%) were the most common comorbidities in COVID-19 patients (Rodriguez-Morales et al. [@CR16]). Our study found similar results with high rates of these comorbidities in severe and ICU groups. For diabetes, a meta-analysis of six studies (1527 patients) found the prevalence to be twice as high in the ICU/severe group compared to non-severe COVID-19 patients (Li et al. [@CR11]). On disaggregating this outcome into two (severe disease and ICU admitted), we found the prevalence of diabetes to be 2.9 times higher in the severe group (compared to non-severe) and 3.6 times higher in the ICU group (compared to non-ICU).

Yang et al. ([@CR25]) performed a meta-analysis of seven studies including 1576 COVID-19 patients. When comparing severe against non-severe patients, the pooled odds ratios of hypertension, respiratory system disease and cardiovascular disease were 2.36 (95% CI 1.46--3.83), 2.46 (95% CI 1.76--3.44) and 3.42 (95% CI 1.88--6.22), respectively. Although we similarly found that comorbidities were not uniform in terms of the risk of severe COVID-19, COPD was an extremely strong predictor for both severe disease and ICU admission---this latter outcome was not investigated separately in the Yang et al. paper (Yang et al. [@CR25]).

We demonstrate that various factors are more strongly associated with ICU admission (representing the very severe end of the disease severity spectrum) compared with less severe disease. The major exception to this was gender. Being male was predictive for ICU admission but not severe disease, with similar proportions of males in both severe and non-severe groups. Given that 70% of 2249 intensive care patients in the UK are male (Intensive care national audit & research centre [@CR9]), and that, of the patients who have died from COVID-19 in Italy, 80% were male (Remuzzi and Remuzzi [@CR15]), this is consistent with empirical data. This suggests that hospitalised COVID-19 patients who are male and have severe disease may be at an increased risk of clinical deterioration requiring ICU admission.

Limitations {#Sec17}
-----------

The foremost limitation of this study was an inability to carry out a multi-variable analysis to account for the presence of several symptoms, comorbidities and potential confounders, such as age. Although this outbreak has seen the evolution of linked data and large open access datasets (Wu and McGoogan [@CR23]) which would be suitable for multi-variable analysis, these currently lack the quality of published data: there are large amounts of missing data, a narrow range of collected variables, and uncertainty about data collection methods and consistency. Our univariable analysis is therefore valuable in evaluating specific individual symptoms and comorbidities predictive for COVID-19 severity and ICU admission using high-quality evidence in the form of peer-reviewed studies.

Secondly, the studies included here were all from China, so the generalisability of findings to other countries and populations is not clear. The Chinese may differ to other populations in terms of their health-seeking behaviour, symptom reporting, prevalence of different comorbidities, as well as their access to high-quality health services. Moreover, because the criteria for ICU admission depends on multiple factors, including bed capacity, this may also differ in other countries, health systems, and at different phases of the epidemic. Nonetheless, given the current dearth of contextually specific evidence available, our findings will help to inform future research and actions.

Finally, it was not possible to account for the timing of presentation in the statistical analysis. If a patient presented after many days of being symptomatic, this may have affected disease severity, compared with an earlier clinical presentation. However, this limitation does not apply to comorbidities, and Table [1](#Tab1){ref-type="table"} shows information from individual studies on median duration of symptoms before admission, which appears similar between severe (or ICU) and non-severe (or non-ICU) cases. It is therefore unlikely that this will have significantly biased the overall results.

Implications for clinical practice/public health {#Sec18}
------------------------------------------------

By identifying the symptoms and comorbidities predictive for severe disease and ICU admission, clinicians can better stratify the risk of individual patients, as early as their initial contact with health services. This can lead to practical changes in management, which can improve allocative efficiency as well as clinical outcomes, through the consideration of more intensive environments of care (e.g. high dependency unit), earlier on, for patients at highest risk of severe infection. These can also be formalised within risk stratification tools to aid clinical decision-making, such as the CURB65 tool for community-acquired pneumonia (Lim et al. [@CR13]). As the number of hospitalised COVID-19 cases continues to increase, hospitals will increasingly need to ration limited resources and improve clinical pathways to effectively prioritise patients with greatest clinical need. Anticipation of future demand, based on local population characteristics, may enable more timely planning and resource mobilisation (Yang et al. [@CR26]). Identifying those at the highest risk will also facilitate better-informed discussions between clinicians, patients and patients' families about the anticipated clinical trajectory, allowing more accurate and timely advance care planning to occur.

Identifying those at high-risk will aid the public health response in controlling the spread of disease. Given the ubiquity of comorbidities in the elderly population, and their increased susceptibility to severe COVID-19 infection (WHO-China Joint Mission [@CR22]), knowledge on the differing prevalence and risk of various conditions may help to focus and tailor public health efforts. For instance, for COPD, which is less common in the general population and very strongly associated with ICU admission, a more targeted and intensive health protection strategy may be warranted, compared to other conditions (such as hypertension) which are more difficult to target due to their higher prevalence in the general population.

Furthermore, if it is found that severity of illness is related to infectivity, as is the case in the closely related SARS-CoV, then identifying patients who may develop severe illness can help guide precautions to prevent the spread of SARS-CoV-2. These include infection control decisions regarding the limited availability of isolation rooms and personal protective equipment (PPE), particularly in more resource-constrained settings.

Implications for future research {#Sec19}
--------------------------------

Specific guidance for future observational cohort studies investigating factors predictive for severe COVID-19 is outlined in Table [4](#Tab4){ref-type="table"}. This is a list of measures researchers can take to improve the quality of research and therefore the utility of study findings. These recommendations are indicative rather than exhaustive and have been made based on the number of limitations identified in the design of studies included in this review. This may not apply to studies investigating different predictive factors or outcomes to those reported here and does not account for the practical or resource constraints researchers may face.Table 4Recommendations for observational cohort studies investigating predictive factors for COVID-19 severityStudy domainRecommendationRationaleDesignProspective design following patients from the community into hospital, during their hospital stay (including progression from ward to ICU), and from hospital back into the community (including patients who are readmitted due to deterioration after discharge)Minimises bias from self-report, objective assessment of temporal relationships, establishes risk directly, can identify factors involved in disease severity at different time points during the entire course of illnessPredictors (i.e. symptoms/comorbidities)Report time of symptom onset to hospitalisation, and time from hospitalisation to ICU admission, where appropriateAids assessment of temporal relationships and minimises risk of bias, allows assessment of the impact of early hospital or ICU admission on disease severityReport time of ascertainment (e.g. symptoms recorded on admission)Aids assessment of temporal relationships and minimises risk of bias (e.g. reverse causality)Report means of ascertainment (e.g. fever according to thermometer or self-report)Minimises risk of instrument or recall bias, improves reliabilityReport each comorbidity separately (e.g. record ischaemic heart disease, stroke and atrial fibrillation as different conditions rather than as one grouped under 'cardiovascular disease')Allows more accurate linking of datasets and aggregate analyses, prevents confounding due to mixing exposures and enables more targeted clinical and public health actionFor comorbidities amenable to treatment (e.g. hypertension, diabetes), include a validated measure of disease control (e.g. BP/HbA1c)Improves internal validity and utility of findings, aids clinical and public health strategy on identifying and managing high-risk groupsInclude other elements of routinely available data from medical records (e.g. medications taken, family history, sociodemographic details including age and ethnicity, lifestyle information including smoking history)Adjusting for these in multi-variable or stratified analysis will minimise confounding from other factors that may be involved in COVID-19 severity and enable a more robust analysis of potential factors involved in disease severityOutcomes (i.e. disease severity)Report time of ascertainment (e.g. severity assessed on admission)Aids assessment of temporal relationships and minimises risk of bias (e.g. reverse causality)Use internationally standardised case definitions for disease severity (e.g. World Health Organisation^a^)Ensures objective and consistent measurement of severity as validated by experts, improves external validityReport severe disease, critical disease and death separatelyMinimises risk of measurement bias, improves accuracy of the estimated effect size for various risk factors in predicting different disease outcomesInclude ICU admission criteria as far as possible (including any blanket exclusion criteria, e.g. end-stage renal failure) and limitations on ICU capacityAdjusting for these in multi-variable or stratified analysis will minimise confounding from other factors that may be involved in ICU admission^a^The WHO-China Joint Mission on COVID-19 defined a severe case of COVID-19 as tachypnoea (≥ 30 breaths/min) or oxygen saturation ≤ 93% at rest, or PaO2/FiO2 \< 300 mmHg (WHO-China Joint Mission [@CR22]). Critical COVID-19 cases were defined as respiratory failure requiring mechanical ventilation, shock or other organ failure that requires intensive care

Conclusions {#Sec20}
-----------

Being male was predictive for ICU admission but not severe disease, suggesting that hospitalised COVID-19 patients who are male and have severe disease may be at an increased risk of clinical deterioration. Dyspnoea was the only symptom strongly predictive for both severe disease and ICU admission and could be a useful symptom to help guide risk assessment and timely clinical management. The association between comorbidities and severe disease was not homogenous. In ICU-admitted patients, who represent the more severe end of the spectrum of clinical severity, the difference in effect sizes for COPD and the other included comorbidities was large, suggesting that COPD patients are particularly vulnerable to very severe (or critical) disease. As the outbreak develops, future research must build on these findings by investigating factors related to disease severity, including a wide range of comorbidities and the effect of various potential confounding factors. This will aid clinical assessment, risk stratification and resource allocation and allow public health interventions to be targeted at the most vulnerable.
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